Light therapy trial shows feasibility of home studies in Parkinson’s

Photopharmics’ Phase 3 clinical trial of its light-based therapy device, Celeste, highlights the growing feasibility and interest in fully remote, home-based studies for Parkinson’s disease. This decentralized approach aims to improve inclusivity by involving patients from rural or underserved areas who typically lack access to traditional clinical trials. Celeste is a tablet-like phototherapy device designed to regulate circadian rhythms, which are often disrupted in Parkinson’s patients, leading to both motor and nonmotor symptoms such as sleep disturbances. Previous trials demonstrated that Celeste improved disease severity, nonmotor symptoms, and quality of life when combined with standard treatments. The ongoing LIGHT-PD trial tests the device in a six-month study where participants use it daily for one hour at home. Remote evaluations assess quality of life, motor, and nonmotor improvements. Early data show that remote consent and software posed challenges, but device setup and neurological assessments were successful. Nearly 3,000 individuals expressed interest, with 125 participants randomized so far. This innovative trial model, presented at the Parkinson Study Group Annual Meeting, underscores the potential of telemedicine to make clinical research more accessible, inclusive, and reflective of real-world conditions.